Clinical trials: Throat Carcinoma
Oropharynx Cancer
Gabapentin for the Reduction of Radiation Therapy Induced Pain During the Treatment of Oropharyngeal Cancer
Strategies to minimize and mitigate external beam radiation therapy related mucositis and pain during the treatment of head and neck cancer remain limited.
- Trial name
- NCT03269344
- Testing
- Gabapentin
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Henry Ford Health System
Head and Neck Cancer, Oropharynx Cancer
Motexafin Gadolinium With Chemotherapy and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer
The purpose of this study is to evaluate the safety of adding the investigational drug Motexafin Gadolinium to the standard treatment of radiation therapy and chemotherapy with drugs called 5-FU and cisplatin in patients with…
- Conditions
- Head and Neck Cancer, Oropharynx Cancer, Larynx Cancer, Hypopharynx Cancer
- Trial name
- NCT00080028
- Testing
- Motexafin Gadolinium Injection
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Pharmacyclics LLC.
Head and Neck Cancer
Photodynamic Therapy Using Porfimer Sodium in Treating Patients With Recurrent Mouth or Throat Dysplasia or Recurrent In Situ Cancer or Stage I Cancer of the Mouth or Throat
RATIONALE: Photodynamic therapy uses a drug that becomes active when it is exposed to a certain kind of light. When the drug is active, tumor cells are killed.
- Trial name
- NCT00530088
- Testing
- porfimer sodium, Photdynamic Therapy (PDT)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Roswell Park Cancer Institute
Nasopharyngeal Carcinoma, Radiation-Induced Temporal Lobe Injury
Retrospective Study on the Prediction of Radiation-induced Brain Injury in Patients With Nasopharyngeal Carcinoma
Radiation therapy has become the preferred treatment for nasopharyngeal cancer due to the sensitivity of nasopharyngeal carcinoma to radiation.
- Trial name
- NCT06244394
- Testing
- intensity-modulated radiotherapy
- Where
- China
- Volunteers
- 230 people
- Sponsor
- Jiangsu Cancer Institute & Hospital
Nasopharyngeal Carcinoma, Recurrent Carcinoma
Bintrafusp Alfa in Previously Treated Patients With R/M Non-keratinizing NPC
This would be a phase II prospective single arm mono-institutional study conducted in Queen Mary Hospital (Hong Kong) assessing the efficacy and safety of bintrafusp alfa in previously treated patients with recurrent and…
- Conditions
- Nasopharyngeal Carcinoma, Recurrent Carcinoma, Metastatic Cancer, Non-keratinizing Carinoma
- Trial name
- NCT04396886
- Testing
- Bintrafusp Alfa
- Where
- Hong Kong
- Volunteers
- 38 people
- Sponsor
- The University of Hong Kong
Nasopharyngeal Carcinoma (NPC), Myelosuppression
Dynamic Risk Prediction of Severe Myelosuppression in Nasopharyngeal Carcinoma
This multicenter, prospective, observational cohort study aims to evaluate a previously developed dynamic risk prediction model for severe treatment-related myelosuppression in patients with nasopharyngeal carcinoma receiving…
- Trial name
- NCT07819656
- Where
- China
- Volunteers
- 1,782 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Nasopharyngeal Neoplasms
PD-1 Blockade Combined With Definitive Chemoradiation in Locoregionally-advanced Nasopharyngeal Carcinoma
This trial plans to enroll 40 patients with stage III-IVA (AJCC 8th, except T3N0-1 or T4N0) locoregionally-advanced nasopharyngeal carcinoma (NPC).
- Trial name
- NCT03619824
- Testing
- Sintilimab, Gemcitabine, Cisplatin
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Cancinoma (NPC)
Tislelizumab Plus Chemotherapy With Response-Adapted Radiotherapy for de Novo Metastatic Nasopharyngeal Carcinoma: A Prospective, Phase II Trial
This study is aimed to evaluate the efficacy and safety of tislelizumab combined with chemotherapy and response-adapted radiotherapy in patients with de novo metastatic nasopharyngeal carcinoma
- Trial name
- NCT07248696
- Testing
- response-adapted radiotherapy
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Chongqing University Cancer Hospital
Head and Neck Cancer, Mucositis Oral
GM-CSF Mouthwash for Preventing and Treating Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer
GM-CSF may protect normal cells from the side effects, such as mucositis, of radiation therapy and may help damaged tissue heal faster after radiation therapy.
- Conditions
- Head and Neck Cancer, Mucositis Oral, Radiation Toxicity, Tongue Cancer
- Trial name
- NCT00293462
- Testing
- sargramostim, oral salt and soda mouthwash
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- Marilyn Dodd
Nasopharyngeal Carcinoma
PET and MRI in Prognosis Prediction of NPC
Nasopharyngeal carcinoma (NPC) differs from other head and neck malignancies terms of its epidemiology, pathology, and treatment outcome.
- Trial name
- NCT03429868
- Testing
- integrated PET/MRI
- Where
- Taiwan
- Volunteers
- 180 people
- Sponsor
- Chang Gung Memorial Hospital
Nasopharyngeal Cancinoma (NPC)
Tislelizumab Combined With Capecitabine for Nasopharyngeal Carcinoma With Residual EBV DNA After Radiotherapy
This study aims to explore the efficacy and safety of tislelizumab combined with capecitabine in nasopharyngeal carcinoma patients with residual plasma EBV DNA after radiotherapy.
- Trial name
- NCT07067268
- Testing
- Adjuvant therapy
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Fudan University
Nasopharyngeal Carcinoma
18F-FMISO PET Guided Dose Escalation in Nasopharyngeal Carcinoma - a Feasibility and Planning Study
This study aims to investigate the use of 18F-FMISO PET in identifying hypoxic subvolume for dose escalation radiotherapy in nasopharyngeal cancer and thus improve local control without significant increase in toxicities.
- Trial name
- NCT04995185
- Testing
- (18)F-fluoromisonidazole (FMISO)
- Where
- 2 sites in Singapore
- Volunteers
- 9 people
- Sponsor
- National Cancer Centre, Singapore
Carcinoma, Nasopharyngeal
Randomized Trial to Evaluate Accelerated Radiotherapy in Locally Advanced Carcinoma of Nasopharynx
The present study is designed as a two arm randomized trial to evaluate the impact of accelerated radiotherapy delivered by image guided radiotherapy with rapid arc technique in carcinoma nasopharynx.
- Trial name
- EARN (NCT04538547)
- Testing
- Accelerated Radiotherapy, Non Accelerated Radiotherapy
- Where
- India
- Volunteers
- 120 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Nasopharyngeal Carcinoma, Lymphomas, Any EBV+ Solid Tumour
Safety and Tolerability Study of RAD001 and LBH589 in All Solid Tumors With Enrichment for EBV Driven Tumors
The purpose of this study is: 1. To determine the optimal recommended phase II dose of two investigational study drugs, LBH589 and RAD001, given in combination in all solid tumors (With enrichment for EBV-Driven tumors). 2.
- Trial name
- NCT01341834
- Testing
- LBH589 and RAD001
- Where
- Singapore
- Volunteers
- 49 people
- Sponsor
- National Cancer Centre, Singapore
Nasopharyngeal Carcinoma
Surgery Plus Target-reduction Chemoradiotherapy vs Regular Chemoradiotherapy for Newly Diagnosed Resectable Nasopharyngeal Carcinoma
Through a prospective clinical trial, we intend to combine surgery, induction chemotherapy, target-reduction intensity-modulated radiotherapy and concurrent chemotherapy as an experimental treatment for patients with newly…
- Trial name
- NCT05352321
- Testing
- Gemcitabine, Cisplatin, regular intensity-modulated radiotherapy
- Where
- 2 sites in China
- Volunteers
- 264 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma, High-Risk Cancer
Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma
N3 classification, rENE positivity is a high-risk type of locally advanced nasopharyngeal carcinoma. EBV DNA remaining at detectable levels after induction chemotherapy is also a characteristic of high-risk nasopharyngeal…
- Conditions
- Nasopharyngeal Carcinoma, High-Risk Cancer, Maintenance Therapy
- Trial name
- NCT06277050
- Testing
- Maintenance Therapy with Toripalimab and Capecitabine, Maintenance Therapy with Capecitabine
- Where
- 3 sites in China
- Volunteers
- 264 people
- Sponsor
- Jiangxi Provincial Cancer Hospital
Head and Neck Cancer
Antineoplaston Therapy in Treating Patients With Advanced Head and Neck Cancer
Current therapies for advanced Head and Neck Cancer provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of advanced Head and Neck…
- Trial name
- NCT00003489
- Testing
- Antineoplaston therapy (Atengenal + Astugenal)
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Burzynski Research Institute
Locally Advanced Malignant Neoplasm, Oral Cancer
Neo-adjuvant Erbitux-based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer
Epidermal growth factor receptor（EGFR） is a potential target for new anticancer therapy in head and neck squamous cell carcinoma, because blocking the EGFR by a monoclonal antibody results in inhibition of the stimulation of the…
- Conditions
- Locally Advanced Malignant Neoplasm, Oral Cancer, Oropharyngeal Carcinoma
- Trial name
- NCT01440270
- Testing
- Neo-adjuvant Erbitux-based chemotherapy
- Where
- 7 sites in China
- Volunteers
- 145 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Nasopharyngeal Carcinoma
Surufatinib Combined With Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma
A prospective, single-arm,mutil-center study to assess the efficacy and safety of Surufatinib combined with Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma.
- Trial name
- NCT04955886
- Testing
- Surufatinib(HMPL-012)
- Where
- 2 sites in China
- Volunteers
- 14 people
- Sponsor
- Fujian Cancer Hospital
Nasopharyngeal Carcinoma
Trial of VELCADE in Patients With Metastatic or Locally Recurrent Nasopharyngeal Carcinoma
This study seeks to test the Efficacy in terms of rates of disease response in metastatic nasopharyngeal carcinoma of the standard dose of velcade 1.3 mg/m2 given at the day 1,4,8,and 11 every 21 days schedule.
- Trial name
- NCT00367718
- Testing
- Velcade
- Where
- 3 sites in China, Singapore
- Sponsor
- Johns Hopkins University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.